Ajanta Pharma is an Indian pharmaceutical company. The headquartered of this company located in Mumbai, Maharashtra, India. Ajanta Pharma Limited was established in 1973 by the Agrawal family. This company develops, manufactures and markets branded generics to emerging markets in 30 plus countries which is across Asia, Africa, CIS, Middle East and SE Asia, and generics to developed markets like the USA. The article is all about Ajanta Pharma Share Price.
About the company
Ajanta Pharma is engaged in the development, manufacturing, and marketing of quality finished dosages. This company is committed to ‘Serve Health Care Needs Worldwide’. Ajanta Pharma produces a comprehensive range of specialty products targeting different therapeutic segments for the treatment of patients, customized to each market we are present in. The business of this company includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Ajanta operates seven states of the art manufacturing facilities in India and Mauritius. In this company two of the facilities in India have been successfully approved by US FDA. In India, this company has a presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management. Ajanta Pharma Limited has been able to provide consistently innovative products, many being first to the market, for patient convenience and compliance. This company’s Institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.
In 1973 Agrawal family founded the company. This company is BSE and NSE listed company from 2000. Ajanta Pharma Limited’s sales and profitability grew at a CAGR of 22.5% and 26.9% respectively of the year FY01 to FY13.
This company employ more than 6000 employees worldwide and sells company’s products across in India, Asia, CIS, Middle East, USA, and Africa. Ajanta Pharma Limited is recently forayed into developed markets for faster growth.
The corporate Office address of Ajanta Pharma Limited is Ajanta House, Charkop, Kandivli West, Mumbai-400 067, Maharashtra, India.
USA Office address of Ajanta Pharma Limited is 440 US Highway 22 East, Suite 150, Bridgewater, NJ 08807, USA.
Mauritius Office address of Ajanta Pharma Limited is BPML Building, Goodlands, Mauritius.
Ajanta Pharma Share Price Graph
Company financials :
Ajanta Pharma Limited is listed on the NSE (National Stock Exchange of India) and the BSE (Bombay Stock Exchange). The pharmaceuticals’ current Market Cap is 8,998.15 cr.
The company report says sales revenues is INR 1728 crores, out of which:
- International business accounted for 69% of total sales.
- The domestic business accounted for 31% of total sales.
Ajanta Pharma Limited had 5 manufacturing facilities and also had 1 Ru0026amp;D Center with:
- 750 plus scientists.
- 6% of sales revenues (2015-16) invested in Ru0026amp;D.
This company was exporting to 30 plus countries across five continents.
Ajanta Pharma Limited had eight of its products approved by US FDA that have either been commercialized or are awaiting launches. This company also provide a domestic presence (in India) in specialty chronic therapies such as Ophthalmology, Dermatology, Cardiology and Pain Management.
Ajanta Pharma Limited had launched 190 plus products in India. This company launched 64 new products in India and emerging markets in 2015-16.
The Board of Directors of the company :
- Mr. Mannalal Agrawal is the Chairman of this company.
- Mr. Purushottam Agrawal is the Vice Chairman of this company.
- Mr. Madhusudan Agrawal is the another Vice Chairman of this company.
- Mr. Yogesh M Agrawal is the Managing Director of this company.
- Mr. Rajesh M Agrawal is the Joint Managing Director of this company.
- Mr. Chandrakant M Khetan is an Independent and Non-Executive Director of this company.
- Mr. KH Vishwanathan is the Independent and Non-Executive Director of this company.
- Dr. Anil Kumar is the Independent and Non-Executive Director of this company.
- Mr. Prabhakar Dalal is also an Independent and Non-Executive Director of this company.
- Dr. Anjana Grewal is an Independent and Non-Executive Director of this company.
Name of the Shareholder :
- Mattews India Fund.
- Motilal Oswal Multicap 35 Fund.
- Sbi Equity Hybrid Fund.
- Kotak Mahindra (International) Limited.
- Foreign Nationals.
- UTI – Equity Fund.
- Non-Resident Indians (Non Repat).
- Non-Resident Indians (Repat).
- Clearing Members.
- Market Maker.
- Bodies Corporate.
News of the company :
As per the date and time (12-11-2018, 06:30 AM) strong export performance, increased capacity utilization and expected revenue and profit boost have made Ajanta Pharma analysts’ top pick. This is the latest news about this company. This company informs that Sun Pharma said the US health regulator USFDA was conducting an inspection of its Mohali facility in Punjab. Ajanta Pharma Limited is bullish about the prospects of its Africa generic business.
According to the news, Ajanta Pharma company net sale September 2018 was at 465.29 cr (down 0.82% in comparison to 469.14 cr in Sept 2017). Net profit also deducted from Rs. 107.70 cr (2017) to Rs. 104.10 cr (2018). EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) stands at the level of Rs. 158.91 crore down from 165.37 cr (2017). EPS (Earnings Per Share) stands at the level of 11.83 from 12.24 (Sept 2017). The company shares closed at 1,010.00 on 30th Oct 2018 and it has given -25.48% return (over the last 6 months) and 18.25% (over the last 12 months).
Now, it’s time to discuss Ajanta Pharma Share Price. Based on the Ajanta Pharma Share Price report, the shareholding pattern of the company is pretty strong. Here is the report:
As per the Sept 18 report, promoters shareholding of the company is 70.47%, public (FII+DII) shareholding is 29.53%. The promoters shareholding percent is pretty good till now. It is expected to see a growth in the company financials in the upcoming years.
Apart from the Ajanta Pharma Share Price, to get more information on other companies, visit our Stock Technical page.